CHO-S [suspension]

A clonal isolate, derived from Chinese hamster ovary (CHO K1) cells. The CHO-S parental cell line was selected for growth and transfection efficiency. CHO-S cells are adapted to serum-free suspension culture.

Cell Type:
Ovary Epith.
Tissue Origin:
ovarian
Species:
hamster
Research Area:
Cancer Research/Cell Biology
Cell Characteristics:
Suspension

Recommended Media

Developed for low density (clonal) growth of CHO cells.

Storage = 2ºC to 8ºC

12-618 = with L-glutamine
BE02-014 = with UltraGlutamine I, without thymidine

Ham's F12 Medium is a nutrient mixture designed to cultivate a wide variety of mammalian and hybridoma cells (including low density (clonal) growth of CHO cells) when used with serum in combination with hormones and transferrin.

ProCHO™ Protein-free CHO Media were developed specifically to facilitate the production and downstream processing of recombinant proteins expressed in CHO cells. These protein-free formulations support high-density cultures without the need for animal derived components.
Very low levels of recombinant insulin facilitate both downstream purification and regulatory compliance.

The following media systems are available:
- ProCHO™ 4 Medium – For concurrent transition of adherent CHO cells to serum-free and suspension culture; supports faster doubling times
- ProCHO™ 5 Medium – For CHO cells already growing in suspension; supports increased protein production
- ProCHO™ AT Medium – For adherent culture of CHO cells

Storage = 2°C to 8°C

12-029Q - ProCHO™ 4 with phenol red and 0.1% Pluronic® F-68; but without L-glutamine, hypoxanthine, or thymidine.
04-919Q - ProCHO™ 4 with 0.1% Pluronic® F-68; and without phenol red, L-glutamine, hypoxanthine, or thymidine.

12-766Q - ProCHO™ 5  with 0.1% Pluronic® F-68; and without L-glutamine, phenol red, hypoxanthine, or thymidine.
BE15-766 - ProCHO™ 5 powder without phenol red

BE02-016 - ProCHO™-AT contains L-glutamine and does not contain hypoxanthine or thymidine.

PowerCHO™ Chemically Defined, Serum-free and hydrolysate-free CHO Media are non-animal origin media designed to support the growth of CHO cell lines, particularly high-density suspension cultures.

For therapeutic bioprocessing applications, these protein-free formulations also facilitate both downstream purification and regulatory compliance.

Storage = 2°C to 8°C

12-770Q - PowerCHO™-1 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
12-771Q - PowerCHO™-2 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
BE15-771N - PowerCHO™-2 powder (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)
12-772Q - PowerCHO™-3 (with HEPES and Pluronic® F-68, without phenol red, hypoxanthine, thymidine, or L-glutamine)

BE12-776Q - PowerCHO™-GS (with HEPES and Pluronic® F-68, without insulin, phenol red or L-glutamine)
PowerCHO™ -GS is designed for use with Lonza's Proprietary GS Gene Expression System™.

12-929Q - PowerCHO™ - Advance

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SG 96-FF-137 2e6 80-92% 43-77% Plasmid (general) 20 µl Shuttle
SG

FF-137

2e6 80-92% 43-67% Plasmid (general) 20 µl 4D X-Unit
V U-024 1e6 90-98% 67-72% Plasmid (general) 5 µg 100 µl I/II/2b

Citations (9)

Categories:
Serum-free and Speciality Media 
Authors:
Pau Serra, Nahir Garabatos, Santiswarup Singha, César Fandos, Josep Garnica, Patricia Solé,Daniel Parras , Jun Yamanouchi, Jesús Blanco, Meritxell Tort, Mireia Ortega, Yang Yang,Kristofor K. Ellestad2 & Pere Santamaria 
In:
Nature (2019) 10: 1 
Categories:
Serum-free and Speciality Media 
Authors:
Anja Sophie Schmid, Dario NeriI 
In:
PLoS ONE (2019) 14: 7 
Categories:
Serum-free and Speciality Media 
Authors:
Ann-Helen Willrodt, Ann-Charlott Salabarria, Philipp Schineis, Desislava Ignatova,Morgan Campbell Hunter, Martina Vranova, Alexandra M. Golding-Ochsenbein,Elena Sigmund, Annatina Romagna, Verena Strassberger, Marina Fabbi,Silvano Ferrini , Claus Cursiefen, Dario Neri, Emmanuella Guenova, Felix Bock andCornelia Halin 
In:
Frontiers in Immunology (2019) 10: 759 
Categories:
Serum-free and Speciality Media 
Authors:
Terme M1, Dorvillius M2, Cochonneau D3, Chaumette T4, Xiao W5, Diccianni MB6, Barbet J3, Yu AL7, Paris F3, Sorkin LS8, Birklé S4. 
In:
PLoS ONE (2014) 9 (2): e103395 
Categories:
Serum-free and Speciality Media 
Authors:
Pasche N1, Wulhfard S, Pretto F, Carugati E, Neri D. 
In:
Clin Cancer Res (2012) 18(15): 4092-103 
Categories:
Transfection 
Authors:
Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, Rebar EJ, Gregory PD, Klug A, Collingwood TN 
In:
Proc Natl Acad Sci USA (2008) 105(15): 5809-14 
Categories:
Transfection 
Authors:
Lattenmayer C, Loeschel M, Schriebl K, Sterovsky T, Trummer E, Vorauer-Uhl K, Muller D, Katinger H, Kunert R 
In:
Biotechnol Bioeng (2007) 96(6): 1118-1126 
Categories:
Transfection 
Authors:
Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, Cortesini R, Suciu-Foca N 
In:
J Immunol (2006) 176(5): 2790-8 
Categories:
Transfection 
Authors:
Rosenblum MD, Woodliff JE, Madsen NA, McOlash LJ, Keller MR and Truitt RL 
In:
J Invest Dermatol (2005) 125(6): 1130-1138 
+ Show All